On 12 February 2015, at the International Stroke Conference (ISC 2015) in Nashville, USA, the findings of a Stroke Association-funded study were presented, called CADISS (Cervical Artery Dissection In Stroke Study).
Can a drug commonly used for gout improve recovery and prevention of further stroke for stroke survivors?
In stroke survivors, does the clinical effectiveness of 6 months treatment with fluoxetine depend upon its effects on synaptic plasticity in the brain? Can a drug used for depression help stroke recovery by changing connections between brain cells?
Disease of the chest portion of the largest artery in the body (the aorta), is known as thoracic aortic disease (TAD). The number of people experiencing TAD is increasing. This study is investigating how to make thoracic endovascular aortic stenting (TEVAR), the preferred method of treating TAD, safer by using extra protection devices.
Can a virtual-reality-home help stroke survivors do better at home?
A research project to find out if a ‘polypill’ can help reduce the chance that people who have had a stroke will have a heart attack or another stroke.
In recent years, legal cannabis-based products containing cannabidiol (CBD), have become more available. Could these help stroke survivors to cope with problematic effects of stroke?
This research will investigate the use of orthitics (for example, braces and splints) early on in a stroke survivor’s rehabilitation. The results will inform a larger study into early orthotic use after stroke.
This study will test arm training to encourage a functionally useful contribution to recovery from the side of the brain unaffected by stroke (the 'non-stroke hemisphere'), and whether this is only possible early after stroke.
Funded by the European Union (EU), a new international study called PROOF will investigate whether high-dose oxygen therapy can reduce the effects of stroke.
The Stroke Association is a member of the Stroke Alliance For Europe (SAFE), which will work on communication of information about the PROOF trial to non-clinical audiences.